Metabolic and cardiovascular risk factors in subjects with impaired fasting glucose: The 100 versus 110 mg/dL threshold

Diabetes/Metabolism Research and Reviews

Volumn 23, Issue 7, 2007, Pages 547-550

  Andreozzi, Francesco ^a   Succurro, Elena ^a   Mancuso, Maria Rosaria ^a   Perticone, Maria ^a   Sciacqua, Angela ^a   Perticone, Francesco ^a   Sesti, Giorgio ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

C reactive protein; Cardiovascular risk factors; Impaired fasting glucose; Impaired glucose tolerance; Metabolic syndrome

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN C; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN BLOOD LEVEL; ITALY; LEUKOCYTE COUNT; LIPOPROTEIN BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETIC ANGIOPATHIES; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 35548968406     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.724     Document Type: Article

References (23)

1. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167.
2. Tai ES, Goh SY, Lee J, et al. Lowering the criteria for impaired fasting glucose: impact on disease prevalence and associated risk of diabetes and ischemic heart disease. Diabetes Care 2004; 27: 1728-1734.
3. Genuth S. Lowering the criterion for impaired fasting glucose is in order. Diabetes Care 2003; 26: 3331-3332.
4. Forouhi NG, Balkau B, Borch-Johnsen K, et al., On behalf of EDEG. The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group. Diabetologia 2006; 49: 822-827.
5. Phillips LS, Weintraub WS, Ziemer DC, Kolm P, Foster JK. All pre-diabetes is not the same: metabolic and vascular risks of impaired fasting glucose at 100 versus 110 mg/dl. The screening for impaired glucose tolerance study 1 (SIGT 1). Diabetes Care 2006; 29: 1405-1407.
6. Wen CP, Cheng TY, Tsai SP, Hsu HL, Wang SL. Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. Diabetes Care 2005; 28: 2756-2761.
7. Sorkin JD, Muller DC, Fleg JL, Andres R. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 2005; 28: 2626-2632.
8. Kanaya AM, Herrington D, Vittinghoff E, et al. Impaired fasting glucose and cardiovascular outcomes in postmenopausal women with coronary artery disease. Ann Intern Med 2005; 142: 813-820.
9. Morita S, Kasayama S, Otsuki M, et al. Atherosderotic risk factors in Japanese subjects with isolated impaired fasting glucose and those with isolated impaired glucose tolerance according to 1997 and 2003 American diabetes association criteria. Diabetes Care 2006; 29: 2123-2126.
10. Sesti G, Sciacqua A, Cardellini M, et al. Plasma concentration of insulin-like growth factor-I is independently associated with insulin sensitivity in subjects with different degree of glucose tolerance. Diabetes Care 2005; 28: 132-137.
11. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-1062.
12. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart association/national Heart, Lung, and Blood Institute scientific statement. Circulation 2005; 112: 2735-2752.
13. Borch-Johnsen K, Colagiuri S, Balkau B, et al. Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia 2004; 47: 1396-1402.
14. Cicero AF, Dormi A, Nascetti S, et al. Relative role of major risk factors for type 2 diabetes development in the historical cohort of the Brisighella Heart Study: an 8-year follow-up. Diabet Med 2005; 22: 1263-1266.
15. Qiao Q, Lindstrom J, Valle TT, Tuomilehto J. Progression to clinically diagnosed and treated diabetes from impaired glucose tolerance and impaired fasting glycaemia. Diabet Med 2003; 20: 1027-1033.
16. Wang JJ, Yuan SY, Zhu LX, et al. Effects of impaired fasting glucose and impaired glucose tolerance on predicting incident type 2 diabetes in a Chinese population with high postprandial glucose. Diabetes Res Clin Pract 2004; 66: 183-191.
17. The DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-404.
18. Nakagami T, DECODA Study Group. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004; 47: 385-394.
19. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002; 359: 1740-1745.
20. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab 2004; 89: 114-120.
21. Spallarossa P, Brunelli C, Minuto F, et al. Insulin-like growth factor-I and angiographically documented coronary artery disease. Am J Cardiol 1996; 77: 200-202.
22. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-1292.
23. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106: 2067-2072.